Synthesis and antimalarial activity of side chain modified 4-aminoquinoline derivatives

Journal of Medicinal Chemistry

Volumn 50, Issue 2, 2007, Pages 394-398

  Raja Solomon, V ^a   Haq, W ^a   Srivastava, Kumkum ^a   Puri, Sunil K ^a   Katti, S B ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOQUINOLINE DERIVATIVE; AQ 13; CHLOROQUINE; HEMATIN; HEME; MEPACRINE; PAMAQUINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; POLYMERIZATION; STRUCTURE ACTIVITY RELATION; SURVIVAL TIME; SWISS WEBSTER MOUSE;

AMINOQUINOLINES; ANIMALS; ANTIMALARIALS; HEMEPROTEINS; MICE; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33846458645     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061002i     Document Type: Article

References (37)

1. (a) Fidock, D. A; Rosenthal, P. J.; Croft, S. L.; Brun, R.; Nwaka, S. Antimalarial Drug Discovery: Efficacy Models For Compound Screening. Nat. Rev. Drug Discovery 2004, 3, 509-519.
2. (b) Wiesner, J.; Ortmann, R.; Schlitzer, M. New Antimalarial Drugs. Angew. Chem., Int. Ed. 2003, 42, 5274-5293.
3. Coatney, G. R.; Cooper, W. C.; Eddy, N. B.; Grennberg, J. Survey of Antimalarial Agents. Public Health Monogr. 1953, 15, 1-322.
4. Greenwood, D. Conflicts of Interest: The Genesis of Synthetic Antimalarial Agents in Peace and War. J. Antimicrob. Chemother. 1995, 36, 857-872.
5. Loeb, R. F.; Clarke, W. M.; Coateney, G. R.; Coggeshall, L. T.; Dieuaide, F. R.; Dochez, A. R.; Hankansson, E. G.; Marshall, E. K.; Marvel, S. C.; McCoy, O. R.; Sapero, J. J., Serbell, W. H.; Shannon, J. A.; Carden, G. A. Activity of a New Antimalarial Agent, Chloroquine (SN 7618). J. Am. Med. Assoc. 1946, 130, 1069-1070.
6. Ridley, R. G. Medical Need, Scientific Opportunity and the Drive for Antimalarial Drugs. Nature 2002, 415, 686-693.
7. (a) Pandey, A. V.; Bisht, H.; Babbarwal, V. K.; Srivastava, J.; Pandey, K. C.; Chauhan, V. S. Mechanism of Malarial Haem Detoxification Inhibition by Chloroquine. Biochem. J. 2001, 355, 333-338.
8. (b) Chou, A. C.; Chevli, R.; Fitch, C. D. Ferriprotoporphyrin IX Fulfills the Criteria for Identification as the Chloroquine Receptor of Malaria Parasites. Biochemistry 1980, 19, 1543-1549.
9. (c) Egan, T. J.; Marques, H. M. The Role of Haem in the Activity of Chloroquine and Related Antimalarial Drugs. Coord. Chem. Rev. 1999, 190-192, 493-517.
10. (d) Dorn, A.; Stoffel, R.; Matile, H.; Bubendorf, A.; Ridley, R. G. Malarial Hemozoin/ β-Hematin Supports Haem Polymerization in the Absence of Protein. Nature 1995, 374, 269-271.
11. (e) Sullivan, D. J., Jr.; Gluzman, I. Y.; Russell, D. G.; Goldberg, D. E. On the Molecular Mechanism of Chloroquine's Antimalarial Action. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 11865-11870.
12. (a) Egan, T. J.; Hunter, R.; Kaschula, C. H.; Marques, H. M.; Misplon, A.; Walden, J. C. Structure-Function Relationships in Aminoquinolines: Effect of Amino and Chloro Groups on Quinoline-Hematin Complex Formation, Inhibition of β-Hematin Formation, and Anti-plasmodial Activity. J. Med. Chem. 2000, 43, 283-291.
13. (b) Kaschula, C. H.; Egan, T. J.; Hunter, R.; Basilico, N.; Parapani, S.; Tarameli, D.; Pasini, E.; Monti, D. Structure-Activity Relationships in 4-Aminoquinoline Antiplasmodials. The Role of the Group at the 7-Position. J. Med. Chem. 2002, 45, 3531.
14. (c) Egan, T. J. Hemozoin (malaria pigement): A Unique Crystalline Drug Target. Targets 2003, 3, 115-124.
15. a. Hematin Binding, Inhibition of Hemozoin Formation, and Parasite Growth. J. Med. Chem. 2003, 46, 3166.
16. (a) Ridley, R. G., Hofheinz, H.; Matile, H.; Jaquet, C.; Dorn, A.; Masciadri, R.; Jolidon, S.; Richter, W. F.; Guenzi, A.; Girometta, M. A.; Urwyler, H.; Huber, W.; Thiathong, S.; Peters, W. 4-Aminoquinoline Analogues of CQ with Shortened Side Chains Retain Activity against CQ-Resistant Plasmodium falciparum. Antimicrobial. Chemother. 1996, 40, 1846-1854.
17. (b) De, D.; Krogstad, F. M.; Byers, L. D.; Krogstad, D. J. Structure-Activity Relationships for Antiplasmodial Activity among 7-Substituted 4-Aminoquinolines. J. Med. Chem. 1998, 41, 4918-4926.
18. Solomon, V. R.; Puri, S. K.; Srivastava, K.; Katti, S. B. Design and Synthesis of New Antimalarial Agents from 4-Aminoquinoline. Bioorg. Med. Chem. 2005, 13, 2157-2165.
19. Stocks, P. A.; Raynes, K. J.; Bray, P. C.; Park, B. K.; O'Neill, P. M.; Ward, S. A.; Novel Short Chain Chloroquine Analogues Retain Activity against Chloroquine Resistant K1 Plasmodium falciparum. J. Med. Chem. 2002, 45, 4975-4983.
20. Madrid, P. B.; Wilson, N. T.; DeRisi, J. L.; Guy, R. K. Parallel Synthesis and Antimalarial Screening of a 4-Aminoquinoline Library. J. Comb. Chem. 2004, 6, 437-442.
21. O'Neill, P. M.; Willock, D. J.; Hawley, S. R.; Bray, P. G.; Storr, R. C.; Ward, S. A.; Park, B. K. Synthesis, Antimalarial Activity, and Molecular Modeling of Tebuquine Analogues. J. Med. Chem. 1997, 40, 437-448.
22. Thayer, A. M. Fighting Malaria: New Antimalarials Drugs are Needed To Ensure that Effective and Affordable Treatments Continue To Be Available and are Not Lost to Parasite Resistance. Chem. Eng. News 2005, 83, 69-82.
23. (a) Prabhakar, Y. S.; Solomon, V. R.; Gupta, M. K.; Katti, S. B. QSAR Studies on Thiazolidines: A Biologically Privileged Scaffold. In Topics in Heterocyclic Chemistry; Gupta, S. P., Ed.; Springer: Berlin, Heidelberg, Germany, 2006; Vol. 4, pp 161-249.
24. (b) Lesyk, R. B.; Zimenkovsky, B. S. 4-Thiazolidones: Centenarian History, Current Status, and Perspectives for Modern Organic and Medicinal Chemistry. Curr. Org. Chem. 2004, 8, 1547-1577.
25. (c) Srivastava, T.; Haq, W.; Katti, S. B. Carbodiimide-Mediated Synthesis of 4-Thiazolidinones by One-Pot Three-Component Condensation. Tetrahedron 2002, 58, 7619-7624.
26. (d) Rawal, R. K.; Srivastava, T.; Haq, W.; Katti, S. B. An Expeditious Synthesis of Thiazolidinones and Metathiazanones, J. Chem. Res. 2004, 368-369.
27. (e) Rawal, R. K.; Solomon, V. R.; Prabhakar, Y. S.; Katti, S. B. Synthesis and QSAR Studies on Thiazolidinones as Anti-HIV Agents. Comb. Chem. High Throughput Screening 2005, 8, 439-443.
28. (f) Rawal, R. K.; Prabhakar, Y. S.; Katti, S. B. 2-(Aryl)-3-furan-2- ylmethyl-thiazolidin-4-ones as Selective HIV-RT Inhibitors. Bioorg. Med. Chem. 2005, 13, 6771-6776.
29. (g) Srivastava, T.; Gaikwad, A. K.; Haq, W.; Sinha, S.; Katti, S. B. Synthesis and Biological Evaluation of 4-Thiazolidinone Derivatives as Potential Antimycobacterial Agents. ARKIVOC 2005, ii, 120-130.
30. (a) Trager, W.; Jensen, J. B. Human Malaria Parasites in Continuous Culture. Science 1976, 193, 673-675.
31. (b) Desjardins, R. E.; Canfield, C. J.; Haynes, J. D.; Chulay, J. D. Quantitative Assessment of Antimalarial Activity In Vitro by Semi-Automated Microdilution Technique. Antimicrob. Agents Chemother. 1979, 16, 710-718.
32. (c) Lambros, C.; Vanderberg, J. P. Synchronization of Plasmodium falciparum Erythrocytic Stages in Culture. J. Parasitol. 1979, 65, 418-420.
33. Egan, T. J.; Ncokazi, K. K. Effects of Solvent Composition and Ionic Strength on the Interaction of Quinoline Antimalarials with Ferriprotoporphyrin IX. J. Inorg. Biochem. 2004, 98, 144-152.
34. (a) Vippagunata, S. R.; Dorn, A.; Matile, H.; Bhattacharjee, A. K.; Karle, J. M.; Ellis, W. Y.; Ridley, R. G.; Vennerstrom, J. L. Structural Specificity of Chloroquine-Hematin Binding Related to Inhibition of Hematin Polymerization and Parasite Growth. J. Med. Chem. 1999, 42, 4630-4639.
35. (b) Vippagunata, S. R.; Dorn, A.; Ridley, R. G.; Vennerstrom, J. L. Characterization of Chloroquine-Hematin Mu-Oxo Dimer Binding by Isothermal Titration Calorimetry. Biochim. Biophys. Acta 2000, 1475, 133-140.
36. (c) Dorn, A.; Vippagunta, S. R.; Matile, H.; Jaquet, C.; Vennerstrom, J. L.; Ridley, R. G. An Assessment of Drug-Hematin Binding as a Mechanism for Inhibition of Hematin Polymerisation by Quinoline Antimalarials. Biochem. Pharmacol. 1998, 55, 727-736.
37. Pallas 3.0, Compu-Drug Chemistry, Ltd.: San Francisco, CA, 1984.